Introduction
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death in both men and women in the United States. The poor prognosis is largely attributed to advanced stage at diagnosis. Over the past decade, palliative chemotherapy has shown survival benefit in patients with advanced disease [Belani et al. 2005; Martoni et al. 2005; Rudd et al. 2005; Sederholm et al. 2005; Fossella et al. 2003; Non-small Cell Lung Cancer Collaborative Group, 1995] . Platinumbased doublet regimens have been established as the current 'standard of care' with improvements in both overall survival (OS) and quality of life [Scagliotti et al. 2008; Belani et al. 2005; Martoni et al. 2005; Rudd et al. 2005; Scagliotti et al. 2002] . Recently, with better understanding of the molecular pathogenesis, targeted agents have been introduced in the treatment of NSCLC. The epidermal growth factor receptor (EGFR) inhibitors have advanced to front-line therapy of patients with tumors that harbor the EGFR tyrosine kinase mutations [Mok et al. 2009; Rosell et al. 2009; Kobayashi et al. 2005] . These are usually continued until disease progression. The addition of bevacizumab to chemotherapy [Reck et al. 2009; Sandler et al. 2006 ] improves the outcome of a select group of patients with NSCLC but has yet to be adopted worldwide. Although these targeted agents are continued indefinitely until progression, cytotoxic chemotherapeutic intervention has been restricted to four to six cycles in treating patients with advanced NSCLC. Continuation of combination chemotherapy beyond four to six cycles only results in added toxicity without a meaningful improvement in response, progression-free survival (PFS) or OS [Pfister et al. 2004 ]. The current practice guideline entails a 'treatment holiday' and introduction of second-line therapy at the time of disease progression [Azzoli et al. 2009; Pfister et al. 2004] .
It is imperative to state that patients who are able to receive second-line interventions represent a select subgroup and again have a modest but significant benefit in overall outcome with treatment. Continued chemotherapeutic intervention with single-agent docetaxel [Fidias et al. 2009] or gemcitabine [Brodowicz et al. 2006 ] has shown improvement in PFS at the expense of side effects in a subset of patients. The concept of maintenance or prolonged therapy has been adopted in other tumor types such as lymphoma, leukemia and colorectal cancer. With the addition of targeted agents, prolonged administration of bevacizumab has been utilized in NSCLC after initial platinum-based chemotherapy. While this is a biologically rational approach, there is no convincing clinical evidence that patient outcomes are improved with such prolonged administration of this targeted therapy. Recently, three randomized phase III studies have documented improvement in outcome with the use of 'maintenance therapy' for patients with advanced stage NSCLC (Table 1) [Cappuzzo et al. 2009; Ciuleanu et al. 2009; Miller et al. 2009] . In this article we discuss current data on maintenance therapy and the implications for routine patient care.
Options for maintenance therapy
The optimal maintenance therapy agent should be associated with improvement in outcome, good patient tolerance and be devoid of cumulative toxicities. In the study by Fidias and colleagues, following four cycles of first-line chemotherapy with carboplatin and gemcitabine, patients with objective disease response or stable disease (SD) were randomized to treatment with immediate docetaxel as maintenance therapy or to delayed docetaxel (control) [Fidias et al. 2009 ]. A total of 562 patients were enrolled in the study. After assessment of response, 309 patients were randomized to either immediate docetaxel or control. There was a clear advantage in PFS with maintenance docetaxel (5.7 months for immediate docetaxel versus 2.7 months for the control group, p ¼ 0.0001). There was a 3-month OS benefit trend with immediate docetaxel (12.7 months in immediate docetaxel arm versus 9.7 months in the control, p ¼ 0.0853), but this did not reach statistical significance. Of the patients randomized to the control arm, only 63% received the planned therapy. Reasons for not initiating planned second-line therapy included toxicity, decline in performance status and the decision by the treating physician not to administer further therapy. In fact, an identical OS of 12.5 months was observed in patients who received docetaxel on either the experimental or control arm of the study. This observation is biased as 37% of the patients on the delayed docetaxel arm despite close follow up did not make it to the second-line therapy. There is at present no optimally effective strategy to identify patients requiring early intervention or maintenance.
To refine maintenance treatment, it would be of immense benefit to see a definite improvement in OS in the intent-to-treat population. This important clinical question was posed in the next trial where immediate pemetrexed was compared with placebo after patients had received four cycles of platinum combination chemotherapy [Ciuleanu et al. 2009 ]. The trial was powered for both improvements in PFS as well as OS. Pemetrexed was chosen for evaluation in the maintenance setting based on its favorable tolerability profile and the ability to administer it for an extended number of cycles. Following frontline platinum-based doublet therapy, nonprogressing patients were randomized to either pemetrexed (441 patients) or placebo (222 patients), at a 2 : 1 randomization. Maintenance therapy with pemetrexed was associated with a superior PFS, the primary endpoint of the study (4 months with maintenance pemetrexed versus 2 months with placebo, p < 0.00001). The OS of all patients was also significantly improved (13.4 months with pemetrexed versus 10.6 months with placebo, p ¼ 0.012). Consistent with previous reports [Scagliotti et al. 2009 ], patients with tumors of squamous histology did not benefit from pemetrexed. The magnitude of improvement in OS for the nonsquamous subset was quite provocative (15.5 months with pemetrexed versus 10.3 months with placebo, p ¼ 0.002). Maintenance pemetrexed was fairly well tolerated without any evidence of excessive or cumulative toxicity. Approximately 67% of patients on the placebo arm went on to receive poststudy therapy. Crossover to pemetrexed on the placebo arm was 2009 ]. Better and validated patient selection strategies will be needed to ensure appropriate treatment assignments based on either tumor or patient characteristics.
The ATLAS study was designed to evaluate bevacizumab plus erlotinib versus bevacizumab alone in the maintenance setting [Miller et al. 2009 ]. Similar to the SATURN trial, the study was designed to show a benefit of erlotinib in the maintenance setting as all patients entered in this study received bevacizumab. A total of 1160 bevacizumab eligible patients were initially enrolled in the study. Patients were treated initially with platinum-based chemotherapy in combination with bevacizumab. Among those, 768 patients were randomized to receive bevacizumab plus erlotinib or bevacizumab alone. A small improvement in PFS was noted with the addition of erlotinib (3.75 months for bevacizumab versus 4.76 months for bevacizumab and erlotinib, p ¼ 0.0012). The OS between the two arms was similar. Similarly, the number of patients who received further therapy at the time of progression was comparable between both arms (55% versus 50%). Combining bevacizumab with erlotinib, however, results in a significant increase in treatment-related toxicities. Thus, three large randomized phase III studies have demonstrated clinical benefit of maintenance therapy in advanced NSCLC using agents that target a specific aspect of tumor biology or that is targeted at particular tumor histology. Recently, Soon and co-workers performed a metaanalysis on 13 randomized trials with 3027 patients (Soon et al. 2009 ). The authors showed that maintenance therapy consistently improved PFS (HR 0.75, CI 0.690.81, p < 0.00001), though the improvement in OS was modest (HR 0.92, CI 0.860.99, p ¼ 0.03). This metaanalysis did not include all of the recent phase III trials of maintenance therapy. It is therefore conceivable that inclusion of this promising dataset may provide the additional statistical power to show the OS benefit of this management strategy.
The issue: proper patient selection for maintenance therapy Compelling evidence demonstrates that early initiation of maintenance therapy prolongs PFS and in some cases also prolongs OS. The recently published phase III trials of maintenance therapy confirmed the earlier observation in the older trials of immediate versus delayed initiation of additional therapy that consistently showed a high attrition rate such that only 5567% patients in the control or placebo arm received second-line therapy at the time of disease progression. Decline in performance status and overall symptomatic deterioration are the main reasons that a third to half of the patients do not make it to second-line 'effective therapy': most of these patients progressed within a short interval of time measured in weeks to months, despite close follow up even in the study setting. The placebo arm is a 'mirror image' of this established treatment standard, i.e. waiting until disease progression before instituting additional therapy. In the clinical practice setting, there is no realistic approach to risk stratify these patients. Hence, offering maintenance therapy to all patients with reasonable clinical condition, especially those with symptoms, should be considered as the new standard. Immediate treatment strategy or maintenance or consolidation is both tolerable and effective. Pemetrexed has been approved both by the European Medicines Agency (EMEA) and FDA for treatment of patients with advanced nonsquamous cell carcinoma in the maintenance setting. For patients with presence of EGFR mutation, erlotinib maintenance is clearly a better option but the recent decision by the United States Oncology Drug Advisory Committee to recommend against its approval in the maintenance setting will curtail its widespread adoption into clinical practice.
Choice of therapeutic agent
The use of nontargeted cytotoxic agents as maintenance or prolonged therapy following initial frontline therapy of NSCLC was associated with some increase in the incidence of treatment-related toxicity and no clear survival advantage (Fidias et al. 2009; Park et al. 2007; Brodowicz et al. 2006; von Plessen et al. 2006; Westeel et al. 2005; Socinski et al. 2002) . These two factors have prevented the widespread adoption of this treatment strategy until the recent report from contemporary trials. Pemetrexed was the first therapeutic agent to demonstrate an OS advantage when used for maintenance of response achieved in the front-line setting. This survival benefit was most pronounced in patients with NSCLC of nonsquamous histology. Similarly, subset analysis of the SATURN trial data showed that while the PFS advantage of erlotinib maintenance cut across histologic subsets of lung cancer, this advantage was most pronounced in the subset of patients with EGFR mutant tumors, with a HR of 0.1 in favor of erlotinib maintenance. The potential implication of the tumor histologyclinical benefit interaction noted with these two agents in the maintenance setting is further underscored by the established improved efficacy of pemetrexed and EGFR tyrosine kinase inhibitors in histologic and molecularly selected patient subsets in the front-line setting. Perhaps, the most effective use of these agents in the maintenance setting may be in such carefully selected patient subset especially in the case of pemetrexed where the subset analysis based on histology was predefined and the study was appropriately powered. While it may be tempting to adopt similar approach with respect to erlotinib maintenance therapy based on the very modest benefit in unselected patient population but a dramatic PFS advantage demonstrated by an unplanned subset (presence of EGFR mutation) analysis of the SATURN trial results, such an approach cannot be justified at present. It is instructive to note that analysis of molecular and clinical predictors of outcome in the pivotal BR.21 phase III trial of erlotinib showed varying degrees of benefit in different molecular subsets without establishing any single predictive marker for a survival advantage on multivariate analysis [Shepherd et al. 2005; Tsao et al. 2005] . Similarly, the INTEREST trial evaluated the noninferiority of gefitinib versus docetaxel in the second-line setting [Kim et al. 2008 ]. Contrary to expectations, molecular analysis revealed no significant treatment by biomarker status interaction and therefore failed to demonstrate any predictive power for EGFR mutation or EGFR copy number by fluorescence in situ hybridization (FISH) for survival advantage when patients were treated with gefitinib [Douillard et al. 2010 ]. These observations highlight the limits of extrapolating predictive power of biomarkers observed in the front-line setting to other treatment settings perhaps due to a progressive evolution and changes in disease biology with time and following specific therapeutic intervention. Future studies of erlotinib maintenance in carefully selected patient population such as those with EGFR-mutant tumors are therefore warranted.
Cost implication of maintenance therapy
It is incontrovertible that the cost of medical care and in particular the overall benefit of the specific therapeutic intervention has assumed greater importance in the US healthcare delivery system and may become an essential component of the overall efficacy assessment for any intervention in the foreseeable future [Fojo and Grady, 2009] . It is therefore no surprise that the potential adoption of maintenance therapy as a therapeutic paradigm in patients with NSCLC following the promising results of recent phase III trials of maintenance therapy has generated passionate discussion regarding the overall cost of therapy. Pharmacoeconomic analyses in the United States and elsewhere showed that second-line therapeutic agents in NSCLC are associated with acceptable quality-adjusted life-years (QALY) with total cost and corresponding QALY of US$37,000, US$39,100 and US$43,800 of 0.42, 0.41, and 0.41, respectively, for erlotinib, docetaxel and pemetrexed [Lyseng-Williamson, 2010; Carlson et al. 2008] . A similar finding was reported from Europe where pemetrexed was found to be more cost effective than docetaxel in patients with nonsquamous NSCLC [Asukai et al. 2010] . However, such analyses may no longer stand up to close scrutiny if the contention that maintenance therapy only represents a more prolonged administration of an effective second-line agent without any additional survival benefit over what is obtained when the drug is administered at the time of disease progression were to be proven. A careful look at the available data showed that the median number of cycles of pemetrexed administered was five cycles in the maintenance setting versus four cycles in the second-line setting [Ciuleanu et al. 2009; Hanna et al. 2004] . Similar data are not yet available for erlotinib but the incremental prolongation of median PFS with erlotinib in the maintenance setting over second-line setting was 12.3 weeks in the SATURN trial versus 9 weeks in BR.21 trial [Cappuzzo et al. 2009; Shepherd et al. 2005] . When situated in the context of the fact that approximately 40% of patients failed to receive potentially beneficial second-line treatment at the time of disease progression due mostly to declining performance status, it may be cost effective to identify such patients and preferentially offer them maintenance therapy instead of the currently accepted 'watch and wait' paradigm.
The recommendations
A number of factors may influence decisions on maintenance therapy. These include patients' overall condition, tumor histology, tumor genetics, prior treatments, quality of life and cost effectiveness. The question again comes down to selecting appropriate regimen for appropriate patients.
In the face of rapid tumor progression and declining performance, maintenance therapy may not be appropriate in such situation. For patients with reasonable performance status, maintenance therapy should be considered early on.
In selecting appropriate regimens, tumor histology and genetics may play a role in decision making for maintenance therapy. Pemetrexed is the only approved agent in the maintenance setting for patients with advanced nonsquamous NSCLC. For patients with squamous cell carcinoma of the lung, agents other than pemetrexed should be considered. Pemetrexed clearly has no benefit in this subgroup. Also, bevacizumab should be avoided in patients with squamous histology. Docetaxel as the maintenance therapy in patients with squamous cell carcinoma of the lung is a possibility but has unproven benefit in survival. EGFR inhibitors, such as gefitinib and erlotinib, have been shown to induce robust response and superior PFS in the frontline therapy of patients with tumors harboring EGFR mutations [Mok et al. 2009 ]. As demonstrated in the SATURN study [Cappuzzo et al. 2009 ], patients with such mutations experienced exceedingly long PFS when used as a maintenance therapy. The concept of maintenance therapy has been introduced in the management of advanced NSCLC changing the overall treatment paradigm.
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